Ann: Permetrex Outperforms Other CBD Topical Products, page-48

The market has done what the market has always done: goes up and goes down. It's a platitude that's quite revealing, yet annoying, but Botians can console themselves by casting the gaze to what lay ahead.
BOT is targeting a $1.5 billion annual revenues for BTX1503 alone and today's announcement was also about delivering that drug where its effects are optimised. 

Q: what we have here?
A:
i)- a drug in phase 2 of a FDA endorsed trial for acne that has outperformed the leading topical drugs in its phase 1 trial (Epiduo and Aczone).

ii)- a drug in phase 2 of a FDA endorsed trial for eczema that has reported a whopping 35% tratment success in its Phase 1- outperforming both Eucrisia and Elidel. That's a $7 billion per year - growing - market in the US alone.

iii)- a drug that is about to complete a phase 1 trial for psoriasis in collaboration with a leading dermatological company - BIOSKIN GMBH a subsidiary of Bausch Health - psoriasis: another multi-billion market.

iv)- a patented technology in Permetrex that is - according to today announcement - a potential serial deal making magnet.

v)- a topical antibiotic that - according to QU 's research - is tens of times more powerful that similar products currently available.

finally
vi)- people that needs the money and can't wait for the sp to hit - quite shortly- 50c.

All IMO, I'm not a financial adviser and no-one should EVER consider my posts as "advise" for any investment.